#United States #San Francisco #Biotech Showcase #Cereno Scientific #JPM Week

Cereno Scientific at JPM Week 2026

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech company from Gothenburg, Sweden, is gearing up for significant engagements at the JPM Week 2026 and the Biotech Showcase in San Francisco, scheduled from January 12 to January 18, 2026. This premier event is recognized as one of the most important annual gatherings for players in the life science sector, including biotech and pharmaceutical companies, investors, analysts, and patient advocacy groups.

The JPM Week aligns with the J.P. Morgan Healthcare Conference, encompassing a wide array of satellite events, partner meetings, and expert presentations. It serves as a bustling hub for discussions that drive innovation and strategic partnerships across the industry.

Cereno Scientific will actively engage in various meetings throughout the week, highlighting their advancements and participating in investment dialogues at the Biotech Showcase, which runs concurrently on January 12-14. This showcase aims to facilitate partnerships and investment opportunities relevant to innovative biotech solutions.

Sten R. Sörensen, the CEO of Cereno Scientific, emphasized the significance of these events for networking with the global biotech and pharmaceutical community. He noted, "This marks a pivotal moment each year for us as we share our progress and explore new collaborations. We have made notable strides in our HDAC inhibitor portfolio, particularly with our lead candidate CS1, which is on the path to a global Phase IIb trial in pulmonary arterial hypertension (PAH)." He also mentioned the promising Phase I data surrounding CS014, generating substantial interest from potential investors.

The company's lead candidate, CS1, functions via epigenetic modulation and positions itself as a novel therapeutic approach targeting the underlying mechanisms of PAH. Clinical trials have showcased CS1's potential to reverse vascular remodeling, enhance right heart function, and significantly improve patients' quality of life. An Expanded Access Program ensures that those who participated in the Phase IIa trial continue to have access to treatment.

In addition to CS1, the company is advancing CS014, another innovative HDAC inhibitor that demonstrated a favorable safety profile during its Phase I trial. This candidate presents a multimodal approach to treating rare cardiovascular and pulmonary diseases, especially idiopathic pulmonary fibrosis (IPF), which has profound unmet medical needs.

Cereno Scientific is also developing CS585, a potent and selective prostacyclin receptor agonist, which has exhibited promising results in preclinical settings. While specific indications for clinical development are not yet assigned, data suggests it could play a significant role in thrombosis prevention with minimal bleeding risks.

The company operates out of GoCo Health Innovation City in Gothenburg and has a U.S.-based subsidiary located in Kendall Square, Boston, Massachusetts. Its commitment to altering the trajectory of treatment for individuals with rare diseases drives its significant focus on innovation and collaboration.

With excitement and anticipation, Cereno Scientific looks forward to a week of fruitful discussions, potential partnerships, and innovations that align with their mission to enhance life for individuals with rare cardiovascular and pulmonary diseases. Interested collaborators and investors can reach out through their media channels or the partnering platform utilized during the Biotech Showcase.

For further inquiries or meeting requests, please contact Tove Bergenholt, Head of IR Communications, at Cereno Scientific.

For more information on Cereno Scientific and their pioneering work, visit www.cerenoscientific.com.